You are here

ESMO

Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst

Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst

Fierce Pharma

Gilead Sciences

Flag link:

Esmo 2020 – can Alkermes succeed where Nektar failed?

Esmo 2020 – can Alkermes succeed where Nektar failed?

EP Vantage

Flag link:

AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

BioSpace

clinical trials

non-small cell lung cancer

Flag link:

Esmo 2020 – More encouraging signs for checkpoint bispecifics

Esmo 2020 – More encouraging signs for checkpoint bispecifics

EP Vantage

Flag link:

Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients

Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients

BioSpace

Mirati Therapeutics

urothelial cancer

Flag link:

#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap

#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap

Endpoints

Bristol-Myers Squibb

esophageal cancer

Flag link:

ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats

ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats

Fierce Pharma

non-small cell lung cancer

Flag link:

Amgen publishes, presents data on therapy with ‘undruggable’ target

Amgen publishes, presents data on therapy with ‘undruggable’ target

MedCity News

non-small cell lung cancer

Flag link:

Esmo 2020 – some backing for Beigene’s unusual combo approach

Esmo 2020 – some backing for Beigene’s unusual combo approach

EP Vantage

urothelial cancer

Flag link:

ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga

ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga

Fierce Biotech

prostate cancer

Flag link:

ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More

ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More

BioSpace

clinical tirals

Flag link:

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question

Fierce Pharma

triple negative breast cancer

Flag link:

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

Fierce Pharma

Flag link:

ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial

ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial

Fierce Pharma

head and neck cancer

clinical trials

Flag link:

ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray

ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray

Fierce Pharma

Flag link:

ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer

Fierce Pharma

metastatic bladder cancer

Flag link:

#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?

#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?

Endpoints

non-small cell lung cancer

Flag link:

Seattle Genetics stays step ahead of rivals with bladder cancer data

Seattle Genetics stays step ahead of rivals with bladder cancer data

BioPharma Dive

Seattle Genetics

clinical trials

Flag link:

ESMO: Alkermes' major I-O hope sees progress across early cancer tests

ESMO: Alkermes' major I-O hope sees progress across early cancer tests

Fierce Biotech

immuno-oncology

Flag link:

Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer

Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer

Seeking Alpha

Mirati Therapeutics

clinical trials

urothelial cancer

Flag link:

Pages